<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002671'>Basal-cell carcinomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e>) are the commonest human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Insight into their genesis came from identification of mutations in the PATCHED gene (PTCH) in patients with the <z:hpo ids='HP_0002671'>basal-cell nevus</z:hpo> syndrome, a <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">hereditary disease</z:e> characterized by multiple <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e> and by developmental abnormalities </plain></SENT>
<SENT sid="2" pm="."><plain>The binding of Sonic hedgehog (SHH) to its receptor, PTCH, is thought to prevent <z:mpath ids='MPATH_458'>normal</z:mpath> inhibition by PTCH of Smoothened (SMO), a seven-span transmembrane protein </plain></SENT>
<SENT sid="3" pm="."><plain>According to this model, the inhibition of SMO signalling is relieved following mutational inactivation of PTCH in <z:hpo ids='HP_0002671'>basal-cell nevus</z:hpo> syndrome </plain></SENT>
<SENT sid="4" pm="."><plain>We report here the identification of activating somatic missense mutations in the SMO gene itself in <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e> from three patients </plain></SENT>
<SENT sid="5" pm="."><plain>Mutant SMO, unlike <z:mp ids='MP_0002169'>wild type</z:mp>, can cooperate with adenovirus E1A to transform rat embryonic fibroblast cells in culture </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, <z:mp ids='MP_0002096'>skin abnormalities</z:mp> similar to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e> developed in transgenic murine skin overexpressing mutant SMO </plain></SENT>
<SENT sid="7" pm="."><plain>These findings support the role of SMO as a signalling component of the SHH-receptor complex and provide direct evidence that mutated SMO can function as an oncogene in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e> </plain></SENT>
</text></document>